Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT03703102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.
Study identification
- NCT ID
- NCT03703102
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 274 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2018
- Primary completion
- Feb 5, 2020
- Completion
- Nov 11, 2020
- Last update posted
- Apr 25, 2024
2018 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kyowa Investigational Site US-19 | Huntington Beach | California | 92647 | — |
| Kyowa Investigational Site US-17 | Irvine | California | 92697 | — |
| Kyowa Investigational Site US-09 | Los Angeles | California | 90033 | — |
| Kyowa Investigational Site US-05 | Santa Ana | California | 92701 | — |
| Kyowa Investigational Site US-10 | Aurora | Colorado | 80010 | — |
| Kyowa Investigational Site US-14 | Clearwater | Florida | 33756 | — |
| Kyowa Investigational Site US-04 | Boston | Massachusetts | 02115 | — |
| Kyowa Investigational Site US-01 | New York | New York | 10029 | — |
| Kyowa Investigational Site US-20 | Charlotte | North Carolina | 28277 | — |
| Kyowa Investigational Site US-11 | Cleveland | Ohio | 44106 | — |
| Kyowa Investigational Site US-08 | Portland | Oregon | 97239 | — |
| Kyowa Investigational Site US-02 | Dallas | Texas | 75230 | — |
| Kyowa Investigational Site US-07 | Galveston | Texas | 77555 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03703102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 25, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03703102 live on ClinicalTrials.gov.